Abstract
In 48 new diagnosed epileptic patients, affected by partial simple or complex seizures with or without secondary generalization, GVG was administered as unique drug at a mean dose of 29 mg/kg/day. Minimum follow-up was 3 months, maximum 12 months. In about 80% of the patients a disappearance or a reduction ≥50% of the seizure frequency was obtained, without significant differences between cryptogenic and symptomatic etiology, thoughout the whole period of observation. Side effects, mainly body weight increment, were usually mild and transitory.
| Original language | Italian |
|---|---|
| Pages (from-to) | 81-82 |
| Number of pages | 2 |
| Journal | Bollettino - Lega Italiana contro l'Epilessia |
| Issue number | 86-87 |
| Publication status | Published - 1994 |
Fingerprint
ASJC Scopus subject areas
- Clinical Neurology
Cite this
MONOTERAPIA CON VIGABATRIN IN SOGGETTI CON EPILESSIA PARZIALE DI NUOVA DIAGNOSI : RISULTATI PRELIMINARI DI UNO STUDIO COLLABORATIVO APERTO. / De Feo, M. R.; Mecarelli, O.; Marciani, M. G.; Striano, S.; Ortenzi, A.; Cerone, G.; D'Alessandro, P.; Onofri, M.
In: Bollettino - Lega Italiana contro l'Epilessia, No. 86-87, 1994, p. 81-82.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - MONOTERAPIA CON VIGABATRIN IN SOGGETTI CON EPILESSIA PARZIALE DI NUOVA DIAGNOSI
T2 - RISULTATI PRELIMINARI DI UNO STUDIO COLLABORATIVO APERTO
AU - De Feo, M. R.
AU - Mecarelli, O.
AU - Marciani, M. G.
AU - Striano, S.
AU - Ortenzi, A.
AU - Cerone, G.
AU - D'Alessandro, P.
AU - Onofri, M.
PY - 1994
Y1 - 1994
N2 - In 48 new diagnosed epileptic patients, affected by partial simple or complex seizures with or without secondary generalization, GVG was administered as unique drug at a mean dose of 29 mg/kg/day. Minimum follow-up was 3 months, maximum 12 months. In about 80% of the patients a disappearance or a reduction ≥50% of the seizure frequency was obtained, without significant differences between cryptogenic and symptomatic etiology, thoughout the whole period of observation. Side effects, mainly body weight increment, were usually mild and transitory.
AB - In 48 new diagnosed epileptic patients, affected by partial simple or complex seizures with or without secondary generalization, GVG was administered as unique drug at a mean dose of 29 mg/kg/day. Minimum follow-up was 3 months, maximum 12 months. In about 80% of the patients a disappearance or a reduction ≥50% of the seizure frequency was obtained, without significant differences between cryptogenic and symptomatic etiology, thoughout the whole period of observation. Side effects, mainly body weight increment, were usually mild and transitory.
UR - http://www.scopus.com/inward/record.url?scp=0028674569&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028674569&partnerID=8YFLogxK
M3 - Articolo
AN - SCOPUS:0028674569
SP - 81
EP - 82
JO - Bollettino - Lega Italiana contro l'Epilessia
JF - Bollettino - Lega Italiana contro l'Epilessia
SN - 0394-560X
IS - 86-87
ER -